Advertisement

Apolipoprotein H: Its relevance to cardiovascular disease

  • M.A. Crook
    Correspondence
    Correspondence address: Dept of Clinical Biochemistry, University Hospital Lewisham, London SE13 6LH, United Kingdom. Tel.: +44 208 333 3000.
    Affiliations
    Dept of Clinical Biochemistry and Metabolic Medicine, University Hospital Lewisham, United Kingdom

    Guy's Hospital, United Kingdom

    St Thomas’ Hospital, United Kingdom

    University of Greenwich, United Kingdom
    Search for articles by this author
      Apolipoprotein H (Apo H) is a single chain glycoprotein consisting of 326 amino acid residues with a molecular weight of about 50kDa and is involved in clotting mechanisms and lipid pathways[

      Muller G, Biering A, Lux E, Richter V. Beta-2 glycoprotein I analysis in patients with hyperlipoproteinaemia, arteriosclerotic occlusive disease and diabetes mellitus. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1983;38:282–4 [English abstract].

      ]. Castro and colleagues report in this journal that plasma concentrations of Apo H are strongly associated with the metabolic syndrome and cardiovascular disease in type 2 diabetic patients and could be considered as a clinical marker of cardiovascular risk. The increased Apo H concentration in these patients was due to its increased liver synthesis. Apo H is attracting interest in the field of cardiovascular disease, diabetes mellitus, haemostasis and lipidology and may provide an exciting link between them but why is this?

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Muller G, Biering A, Lux E, Richter V. Beta-2 glycoprotein I analysis in patients with hyperlipoproteinaemia, arteriosclerotic occlusive disease and diabetes mellitus. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1983;38:282–4 [English abstract].

        • Lee N.S.
        • Brewer H.B.
        • Osborne J.C.
        Beta-2 glycoprotein I. Molecular properties of an unusual apolipoprotein, apolipoprotein H.
        J Biol Chem. 1983; 258: 4765-4770
        • Polz E.
        • Kostner G.M.
        Binding of beta-2-glycoprotein-I to human-serum lipoproteins – distribution among density fractions.
        FEBS Lett. 1979; 102: 183-186
        • Gambino R.
        • Ruiu G.
        • Pagano G.
        • Cassader M.
        The binding of apolipoprotein H (beta2-blycoprotein I) to lipoproteins.
        Prostaglandins Other Lipid Mediat. 1999; 57: 351-359
        • Zahedi R.
        • Summers L.
        • Lumb P.
        • Chik G.
        • Crook M.
        The response of serum apolipoprotein H to an oral fat load.
        Ann Clin Biochem. 2004; 41: 330-334
        • Agar Ç.
        • de Groot P.G.
        • Levels H.J.
        • Arnoud Marquart J.
        • Meijers J.C.M.
        B2-Glycoprotein I is incorrectly named apolipoprotein H.
        J Thromb Haemost. 2009; 7: 235-236
        • McNeil H.P.
        • Simpson R.J.
        • Chesterman C.N.
        • Krillis S.A.
        Antiphospholipid antibodies are directed at a complex antigen that includes a lipid binding inhibitor of coagulation: apolipoprotein H.
        Proc Natl Acad Sci. 1990; 87: 4120-4124
        • Shi W.
        • Chong B.H.
        • Hogg P.J.
        • Chesterman C.N.
        Anticardiolipin antibodies block the inhibition by beta-2-glycoprotein-I of the factor Xa generating activity of platelets.
        Thromb Haemost. 1994; 71: 526-527
        • Nakaya Y.
        • Schaefer E.J.
        • Brewer H.B.
        Activation of human post heparin lipoprotein lipase by apolipoprotein H.
        Biochim Biophys Res Commun. 1980; 95: 1168-1172
        • Wurm H.
        • Beubler E.
        • Polz E.
        • Holasek A.
        • Kostner G.
        Studies on the possible function of beta-2-glycoprotein-I: influence in the triglyceride metabolism of the rat.
        Metabolism. 1982; 31: 484-486
        • Nimpf J.
        • Wurm H.
        • Kostner G.M.
        Interaction of beta-2-glycoprotein-I with human blood platelets: influence upon ADP induced aggregation.
        Thromb Haemost. 1985; 54: 397-401
        • Valesini G.
        • Shoenfeld Y.
        A new player in the antiphospholipid syndrome: the beta-2-glycoprotein cofactor.
        Autoimmunity. 1992; 14: 105-110
        • Chonn A.
        • Semple S.C.
        • Cullis P.R.
        Beta2-glycoprotein I is a major protein associated with very rapidly cleared liposomes in vivo, suggesting a significant role in the immune clearance of ‘non-self’ particles.
        J Biol Chem. 1995; 270: 25845-25849
        • Thiagarajan P.
        • Le A.
        • Benedict C.R.
        Beta(2)-glycoprotein I promotes the binding of anionic phospholipid vesicles by macrophages.
        Arterioscler Thromb Vasc Biol. 1999; 19: 2807-2811
        • Ma K.
        • Simantov R.
        • Zhang J.C.
        • et al.
        High affinity binding of beta 2-glycoprotein I to human endothelial cells is mediated by Annexin II.
        J Biol Chem. 2000; 275: 15541-15548
        • Matsuura E.
        • Kobayashia K.
        • Koikeb T.
        • et al.
        Atherogenic autoantigen: oxidized LDL complexes with beta2-glycoprotein I.
        Immunobiology. 2003; 207: 17-22
        • Lopez L.R.
        • Hurley B.L.
        • Simpson D.F.
        • Matsuura E.
        Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies in patients with type 2 diabetes mellitus.
        Ann N Y Acad Sci. 2005; 1051: 97-103
        • Matsuura E.
        • Kobayashi K.
        • Hurley B.L.
        • Lopez L.R.
        Atherogenic oxidized low-density lipoprotein/beta2-glycoprotein I (oxLDL/beta2GPI) complexes in patients with systemic lupus erythematosus and antiphospholipid syndrome.
        Lupus. 2006; 15: 478-483
        • Kobayashi K.
        • Kishi M.
        • Atsumi T.
        • et al.
        Circulating oxidized LDL forms complexes with beta2-glycoprotein I: implication as an atherogenic autoantigen.
        J Lipid Res. 2003; 44: 716-726
        • Lopez D.
        • Garcia-Valladares I.
        • Palafox-Sanchez C.A.
        • et al.
        Oxidized low-density lipoprotein/beta2-glycoprotein I complexes and autoantibodies to oxLig-1/beta2-glycoprotein I in patients with systemic lupus erythematosus and antiphospholipid syndrome.
        Am J Clin Pathol. 2004; 121: 426-436
        • George J.
        • Afek A.
        • Gilburd B.
        • et al.
        Induction of early atherosclerosis in LDL receptor deficient mice immunized with beta 2 glycoprotein I.
        Circulation. 1998; 15: 1108-1115
        • Afek A.
        • George J.
        • Shoenfeld Y.
        • et al.
        Enhanced atherosclerosis in apoE deficient mice by immunization with b2-glycoprotein I.
        Pathobiology. 1999; 67: 19-25
        • George J.
        • Harats D.
        • Gilburd B.
        • et al.
        Adoptive transfer of b2-glycoprotein I (b2GPI)-reactive lymphocytes enhances early atherosclerosis in LDL receptor deficient mice.
        Circulation. 2000; 102: 1822-1827
        • Visvanathan S.
        • McNeil H.P.
        Cellular immunity to beta 2-glycoprotein-1 in patients with the antiphospholipid syndrome.
        J Immunol. 1999; 162: 6919-6925
        • Hattori N.
        • Kuwana M.
        • Kaburaki J.
        • et al.
        T cells that are autoreactive to beta2- glycoprotein I in patients with antiphospholipid syndrome and healthy individuals.
        Arthritis Rheum. 2000; 43: 65-75
        • Cassader M.
        • Ruiu G.
        • Gambino R.
        • Veglia F.
        • Pagano G.
        Apolipoprotein H concentrations in diabetic subjects: correlation with cholesterol concentrations.
        Metabolism. 1997; 46: 522-525
        • Cavallo Perin P.
        • Gruden G.
        • Giunti S.
        • et al.
        Apolipoprotein H is increased in type 2 diabetic patients with microalbuminuria.
        Nutr Metab Cardiovasc Dis. 2000; 10: 311-314
        • Crook M.
        • Ch’ng S.I.
        • Lumb P.J.
        Serum apolipoprotein H and its relationship to lipids and other apolipoproteins in normal human men and women.
        Blood Coagulation Fibrinol. 1999; 10: 197-200
        • Crook M.
        • Ch’ng S.I.
        • Lumb P.
        • Reid F.
        Serum apolipoprotein H and its relationship to blood pressure, serum lipids, fasting plasma glucose and insulin in normal individuals.
        Ann Clin Biochem. 2001; 38: 494-498
        • McNally T.
        • Crook M.
        • Mackie I.J.
        • Isenberg D.A.
        • Machin S.J.
        Beta-2-glycoprotein-I antigen is increased in primary hyperlipidaemia.
        Br J Haem. 1993; 88: 424-426
        • McNally T.
        • Mackie I.J.
        • Isenberg D.A.
        • Machin S.J.
        Immunoelectrophoresis and ELISA techniques for assay of plasma beta-2-glycoprotein-I and the influence of plasma lipid.
        Thromb Res. 1993; 72: 275-282
        • Hoeg J.M.
        • Segal P.
        • Gregg R.E.
        • et al.
        Characterisation of plasma lipids and lipoproteins in patients with beta-2-glycoprotein I deficiency.
        Atherosclerosis. 1985; 55: 25-34
        • Sepehrnia B.
        • Kamboh M.I.
        • Adams-Campbell L.L.
        • et al.
        Genetic studies of human apolipoproteins. Role of Apo H polymorphism in relation to serum lipoprotein concentrations.
        Hum Genet. 1989; 82: 118-122
        • Eichner J.E.
        • Kuller L.H.
        • Kamboh M.I.
        • Ferrell R.E.
        Phenotypic effects of apolipoprotein structural variation on lipid profiles. Apo H and quantitative lipid measures in the healthy women study.
        Genet Epidemiol. 1989; 6: 311-318
        • Crews D.E.
        • Kamboh M.I.
        • Mancilha-Carvalho J.J.
        • Kottke B.
        Population genetics of apolipoprotein A-4-E and H polymorphisms in Yanomami Indians of northwestern Brazil: associations with lipids, lipoproteins and carbohydrate metabolism.
        Hum Biol. 1993; 65: 211-224
        • Saha N.
        • Kamboh M.I.
        • Ahn Y.A.
        • Tay J.S.
        • Ferrell R.E.
        Apolipoprotein H polymorphism and serum lipoprotein and apolipoprotein concentrations in two Asian populations.
        Ethnicity Dis. 1993; 3: 250-254
        • Kamboh M.I.
        • Wagenknecht D.R.
        • McIntyre J.A.
        Heterogeneity of the apolipoprotein H3 allele and its role in affecting the binding of apolipoprotein H to anionic phospholipids.
        Hum Genet. 1995; 95: 385-388
        • Cassader M.
        • Ruiu G.
        • Gambino R.
        • et al.
        Influence of apolipoprotein H polymorphism on concentrations of triglycerides.
        Atherosclerosis. 1994; 110: 45-51
        • Kamboh M.I.
        • Sanghera D.K.
        • Mehdi H.
        • et al.
        A Single nucleotide polymorphisms in the coding region of the apolipoprotein H (beta2-glycoprotein I) gene and their correlation with the protein polymorphism, anti beta2glycoprotein I antibodies and cardiolipin binding: description of novel haplotypes and their evolution.
        Ann Hum Genet. 2004; 68: 285-299